Medibiofarma S.L. announced the award of the European CommissionSeal of Excellence for their clinical asset MBF-015.

Navarra – February 2025 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new small molecule therapies announced the award of the European Commission Seal of Excellence for their clinical asset MBF-015. The project, under the title “Re-Spark – MBF-015. A first-in-class disease-modifying therapy to halt cognitive decline” was presented to the European Innovation Council (EIC) Accelerator funding program and was recognised as a high-quality proposal. MBF-015 is a patented new chemical entity which acts as an inhibitor of both HDAC1 and HDAC2 and has demonstrated synaptogenic effects in animal models. MBF-015 has recently completed a first proof-of-concept phase IIa clinical trial in patients with Huntington’s disease where it has demonstrated a good safety profile as well as its capacity to cross the blood brain barrier. Richard Roberts, CSO of Medibiofarma said, “The Seal of Excellence recognizes the scientific rationale to slow cognitive decline and the hard work of the whole team behind the development of MBF-015. This award further confirms our commitment to advancing this project and developing a disease-modifying treatment for Huntington’s and other neurodegenerative diseases which patients so badly need” About Huntington’s Disease Huntington’s disease (HD) is an autosomal dominant neurological disease that afflicts around one in 10,000 people. HD onset typically occurs in young adult life, and the disease is invariably fatal. Patients initially develop small choreic movements that later intensify in amplitude and frequency, causing an impairment of daily activities. Cognitive and psychiatric alterations are often the most disabling symptoms for patients with HD and are among the most difficult symptoms to treat. They are initially subtle and may go unnoticed for years but become significant later in the course of the disease, manifesting as dementia and difficulties in executive functioning. Currently available medications target selected symptoms, but do not provide a cure or slow its progression. About Medibiofarma Medibiofarma is a private biopharmaceutical company founded in 2016, devoted to the discovery and development of new chemical entities against relevant molecular targets, with the aim of improving the lives of patients suffering from neurological, gastrointestinal and oncological diseases. Based on its internal capabilities in medicinal chemistry along with an experienced drug discovery management team, Medibiofarma has developed three projects in its pipeline to early clinical stage, in different therapeutic areas. For more information, please visit Medibiofarma’s website (www.medibiofarma.com).

The release as fetched from its publisher. medibiofarma.com ↗